Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ASPI
ASPI logo

ASPI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
5.875
Open
5.785
VWAP
5.78
Vol
4.17M
Mkt Cap
730.24M
Low
5.660
Amount
24.10M
EV/EBITDA(TTM)
--
Total Shares
125.90M
EV
670.00M
EV/OCF(TTM)
--
P/S(TTM)
20.38
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. Its proprietary technologies, the Aerodynamic Separation Process and Quantum Enrichment technology, are designed to enable the production of isotopes used in several industries. Its initial focus is on the production and commercialization of enriched Carbon-14 (C-14), Silicon-28 (Si-28) and Ytterbium-176 (Yb-176). It is also a provider of liquid helium with operations at the Virginia Gas Project in South Africa. Its nuclear fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate isotopes for highly specialized target end markets.
Show More

Events Timeline

(ET)
2026-05-11
09:20:00
ASP Isotopes Subsidiary Signs MOU with European Nuclear Tech Company
select
2026-04-07 (ET)
2026-04-07
08:50:00
Largest Indicative Borrow Rate Increases Among Liquid Option Names
select
2026-03-24 (ET)
2026-03-24
08:00:00
ASP Isotopes Partners with University of Bristol to Design Lithium Laser Research Facility
select
2026-03-06 (ET)
2026-03-06
16:10:00
U.S. Nonfarm Payrolls Miss Expectations, Unemployment Rate Rises to 4.4%
select
2026-03-06
12:10:00
U.S. February Jobs Data Disappoints, Stocks Drop Sharply
select

News

stocktwits
7.5
05-11stocktwits
ASP Isotopes Signs MoU with European Company for HALEU Supply
  • MoU Extended to 2030: ASP Isotopes' subsidiary Quantum Leap Energy has signed a memorandum of understanding (MoU) with a European nuclear technology company that extends through 2030, establishing a framework for the European partner to supply uranium feedstock to QLE, thereby laying the groundwork for future nuclear energy supply.
  • Rising Demand for HALEU: With increasing demand for high assay low-enriched uranium (HALEU), particularly among advanced nuclear reactor developers, ASP Isotopes' shares rose nearly 5% in Monday's pre-market trading, reflecting strong market interest in securing non-Russian uranium supplies.
  • Potential Delivery Timeline: The MoU outlines that potential uranium deliveries could begin in 2028 and scale up through 2036, depending on reactor development timelines and fuel demand, indicating the company's strategic foresight in aligning with future market needs.
  • Diversified Business Strategy: ASP Isotopes is not only focused on nuclear energy but also shows potential in AI data centers and semiconductor chips, with retail sentiment around its stock remaining neutral, suggesting investor attention and expectations regarding its diversified strategic initiatives.
Newsfilter
7.5
05-11Newsfilter
ASP Isotopes Signs MOU with Quantum Leap Energy for HALEU Supply
  • Strategic Partnership: ASP Isotopes has signed a non-binding MOU with Quantum Leap Energy to explore long-term collaboration with a European nuclear technology firm, aiming to address the growing global demand for high assay low enriched uranium (HALEU), which is expected to enhance the company's competitiveness in the nuclear energy market.
  • Technical Assessment Plan: Under the MOU, both parties will conduct a technical and economic assessment to determine the feasibility of HALEU supply, covering operational requirements, production scalability, and commercial models, which are crucial for supporting future nuclear energy projects.
  • Rising Market Demand: The global demand for HALEU is increasing, particularly from next-generation reactor developers, and the signing of this MOU signifies a significant step for QLE in meeting both domestic and international customer needs, potentially strengthening its market position.
  • Timeline and Deliveries: The MOU is effective until December 31, 2030, with potential HALEU deliveries expected to begin in 2028 and scale up according to the partner's reactor development timeline, indicating QLE's strategic positioning within the nuclear fuel supply chain.
Newsfilter
5.0
05-06Newsfilter
ASPI Appoints Dr. Peter S. Fiske to Quantum Leap Energy's Advisory Board
  • Advisory Board Appointment: ASPI's wholly-owned subsidiary Quantum Leap Energy (QLE) has appointed Dr. Peter S. Fiske to its Strategic Advisory Board, aiming to enhance the company's leadership and execution capabilities in the nuclear energy market through his extensive experience in technology commercialization and government collaboration, thereby accelerating strategic development in the clean energy sector.
  • Commercialization Expertise: Dr. Fiske previously served as the Executive Director of the U.S. Department of Energy's $110 million Water Innovation Hub, overseeing research aimed at reducing water treatment costs and energy requirements, which will provide crucial technical guidance and policy support for QLE's nuclear fuel solution development.
  • Accelerated Organizational Development: This appointment comes at a pivotal moment as QLE accelerates its organizational development and strategic initiatives, following the appointment of Dr. Nate Salpeter as Chief Technology Officer and a collaboration with the University of Bristol to design a state-of-the-art lithium laser research facility, showcasing its growth momentum in advanced nuclear fuel technologies.
  • Growing Market Demand: As governments and energy sector partners increasingly rely on advanced nuclear fuel technologies, Dr. Fiske's addition will further enhance QLE's capabilities in meeting clean energy goals and energy security, driving an increase in the company's market share in mission-critical infrastructure.
Newsfilter
7.5
04-13Newsfilter
ASP Isotopes Provides Business Update for 2026
  • Commercial Shipment Expectations: ASP Isotopes anticipates first commercial shipments of Silicon-28, Carbon-14, and Ytterbium-176 in 2026, marking a significant milestone in the scale-up of its isotope enrichment technology, which is expected to drive revenue growth in the nuclear medicine and electronics sectors.
  • Financial Target Setting: The company has set an EBITDA target of over $300 million by 2031, reflecting confidence in future profitability, while cash and cash equivalents reached $333 million as of December 31, 2025, providing a solid financial foundation to achieve this goal.
  • Nuclear Medicine Progress: The company successfully shipped its first enriched Yb-176 sample in 2025 and plans to achieve commercial shipments by mid-2026, further solidifying its market position in nuclear medicine and expected to boost revenue from related operations.
  • Integrated Electronics Gas Platform Development: ASP Isotopes is building a fully integrated electronic gases platform, targeting the shipment of enriched Silicon-28 products in Q2 2026, aimed at meeting the demands of global semiconductor fabrication facilities and enhancing the company's competitiveness in the high-tech industry.
Globenewswire
7.0
04-10Globenewswire
Investigation into ASP Isotopes Shareholder Claims
  • Securities Fraud Investigation: Grabar Law Office is investigating ASP Isotopes for potential violations of federal securities laws, as the company and its executives allegedly made materially false and misleading statements regarding uranium enrichment technology, which could lead to shareholder losses.
  • Capital Raising Impact: The lawsuit claims that ASP Isotopes raised approximately $18.6 million before September 2024 through misleading statements that were never substantiated by actual testing, resulting in artificially inflated stock prices and harming investor interests.
  • Legal Consequences: The U.S. District Court for the Southern District of New York has partially denied the defendants' motion to dismiss, allowing certain securities fraud claims to proceed, which may expose the company to greater legal liabilities and financial repercussions.
  • Shareholder Action Recommendations: Shareholders holding ASP Isotopes stock are encouraged to seek corporate reforms and fund recovery, with Grabar Law Office offering no-cost legal support, highlighting a commitment to protecting shareholder rights.
Newsfilter
8.5
04-10Newsfilter
ASP Isotopes to Host Business Update Conference Call
  • Business Update Call: ASP Isotopes will host a business update conference call on April 13, 2026, at 8:00 AM ET, aimed at providing investors and the public with detailed insights into the company's latest developments and future strategies, thereby enhancing transparency and investor confidence.
  • Technology Platform Overview: The company is focused on developing a differentiated isotope enrichment platform to strengthen global supply chain access to critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy, driving technological advancements and market competitiveness in these sectors.
  • Forward-Looking Statements: During the call, management may issue forward-looking statements regarding future business plans, anticipated production quantities, and market trends, reflecting the company's positive outlook on future developments and potential risks.
  • International Business Expansion: ASP Isotopes operates isotope enrichment facilities in Pretoria, South Africa, focusing on the enrichment of low atomic mass elements, indicating the company's strategic positioning in the global market and its emphasis on international business growth.
Wall Street analysts forecast ASPI stock price to rise
2 Analyst Rating
Wall Street analysts forecast ASPI stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
11.00
Averages
12.00
High
13.00
Current: 0.000
sliders
Low
11.00
Averages
12.00
High
13.00
Cantor Fitzgerald
Derek Soderberg
Overweight
initiated
$13
AI Analysis
2025-12-04
Reason
Cantor Fitzgerald
Derek Soderberg
Price Target
$13
AI Analysis
2025-12-04
initiated
Overweight
Reason
Cantor Fitzgerald analyst Derek Soderberg initiated coverage of ASP Isotopes (ASPI) with an Overweight rating and $13 price target. ASP Isotopes has developed advanced isotope-enrichment technology that produces high-value nuclear fuel, medical isotopes, and silicon-28, and currently stands as the sole commercial-scale provider of certain isotopes, the analyst tells investors in a research note. The pending acquisition of Renergen (RGNNF) could give ASPI control of the world's largest high-concentration helium deposit, while the planned spinout of its quantum laser enrichment technology represents a near-term value-creation opportunity, Cantor says.
Cantor Fitzgerald
Derek Soderberg
initiated
$13
2025-12-04
Reason
Cantor Fitzgerald
Derek Soderberg
Price Target
$13
2025-12-04
initiated
Reason
Cantor Fitzgerald analyst Derek Soderberg initiated coverage of ASP Isotopes with an Overweight rating and $13 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ASPI
Unlock Now

Valuation Metrics

The current forward P/E ratio for ASP Isotopes Inc (ASPI.O) is 54.35, compared to its 5-year average forward P/E of -8.99. For a more detailed relative valuation and DCF analysis to assess ASP Isotopes Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.99
Current PE
54.35
Overvalued PE
21.65
Undervalued PE
-39.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.74
Current EV/EBITDA
-6.45
Overvalued EV/EBITDA
32.81
Undervalued EV/EBITDA
-38.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
14.77
Current PS
9.27
Overvalued PS
25.45
Undervalued PS
4.09

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what $5-10 stocks are surging on Tuesday
Intellectia · 88 candidates
Price: $5.00 - $10.00Price Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
MTC logo
MTC
MMTEC Inc
718.03M
SKIL logo
SKIL
Skillsoft Corp
47.76M
ROLR logo
ROLR
High Roller Technologies Inc
55.43M
RVYL logo
RVYL
Ryvyl Inc
6.30M
BYRN logo
BYRN
Byrna Technologies Inc
148.36M
OSS logo
OSS
One Stop Systems Inc
219.17M
penny stocks
Intellectia · 52 candidates
Market Cap: 100.00M - 1.50BPrice: $0.50 - $5.00Volume: >= 1,000,000Price Change Pct: $-100.00 - $100.00List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 10,000,000
Ticker
Name
Market Cap$
top bottom
CTMX logo
CTMX
CytomX Therapeutics Inc
949.02M
SIDU logo
SIDU
Sidus Space Inc
282.71M
RZLV logo
RZLV
Rezolve AI PLC
800.46M
SLS logo
SLS
Sellas Life Sciences Group Inc
854.81M
GERN logo
GERN
Geron Corp
1.07B
WTI logo
WTI
W&T Offshore Inc
410.63M
list penny stocks
Intellectia · 67 candidates
Market Cap: 100.00M - 1000.00MRegion: USPrice: $1.00 - $5.00Quarter Revenue Yoy Growth: >= 10.0%List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
BTBT logo
BTBT
Bit Digital Inc
466.09M
VERI logo
VERI
Veritone Inc
239.61M
HIVE logo
HIVE
HIVE Digital Technologies Ltd
488.79M
PACB logo
PACB
Pacific Biosciences of California Inc
407.70M
MNKD logo
MNKD
MannKind Corp
708.63M
BLDP logo
BLDP
Ballard Power Systems Inc
737.24M
best strong buy for today
Intellectia · 86 candidates
Analyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
CING logo
CING
Cingulate Inc
43.41M
CATX logo
CATX
Perspective Therapeutics Inc
261.77M
ELVN logo
ELVN
Enliven Therapeutics Inc
1.51B
ADTN logo
ADTN
ADTRAN Holdings Inc
757.90M
UTI logo
UTI
Universal Technical Institute Inc
1.52B
CNTA logo
CNTA
Centessa Pharmaceuticals PLC
3.82B
find me the next stock like opgn
Intellectia · 31 candidates
Quarter Revenue Yoy Growth: >= 20.0%Market Cap Category: small, microBeta: HighRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
GLUE logo
GLUE
Monte Rosa Therapeutics Inc
1.85B
SNDX logo
SNDX
Syndax Pharmaceuticals Inc
1.78B
HROW logo
HROW
Harrow Inc
1.75B
TNGX logo
TNGX
Tango Therapeutics Inc
1.68B
STOK logo
STOK
Stoke Therapeutics Inc
1.68B
NTLA logo
NTLA
Intellia Therapeutics Inc
1.63B

Whales Holding ASPI

E
Encompass Capital Advisors LLC
Holding
ASPI
+23.10%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is ASP Isotopes Inc (ASPI) stock price today?

The current price of ASPI is 5.8 USD — it has decreased -4.76

What is ASP Isotopes Inc (ASPI)'s business?

ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. Its proprietary technologies, the Aerodynamic Separation Process and Quantum Enrichment technology, are designed to enable the production of isotopes used in several industries. Its initial focus is on the production and commercialization of enriched Carbon-14 (C-14), Silicon-28 (Si-28) and Ytterbium-176 (Yb-176). It is also a provider of liquid helium with operations at the Virginia Gas Project in South Africa. Its nuclear fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate isotopes for highly specialized target end markets.

What is the price predicton of ASPI Stock?

Wall Street analysts forecast ASPI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASPI is12.00 USD with a low forecast of 11.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is ASP Isotopes Inc (ASPI)'s revenue for the last quarter?

ASP Isotopes Inc revenue for the last quarter amounts to 16.66M USD, increased 1295.41

What is ASP Isotopes Inc (ASPI)'s earnings per share (EPS) for the last quarter?

ASP Isotopes Inc. EPS for the last quarter amounts to -0.76 USD, increased 442.86

How many employees does ASP Isotopes Inc (ASPI). have?

ASP Isotopes Inc (ASPI) has 271 emplpoyees as of May 17 2026.

What is ASP Isotopes Inc (ASPI) market cap?

Today ASPI has the market capitalization of 730.24M USD.